Assert-IQ vs Cardiomo

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Abbott Medical
VS
by Cardiomo, Inc.

AI Verdict

Assert-IQ and Cardiomo both offer AI-powered cardiac monitoring, but they target different use cases. Assert-IQ is an insertable cardiac monitor designed for long-term, continuous professional diagnosis and management of suspected heart rhythm disorders within a clinical setting. Cardiomo, on the other hand, provides a medical-grade wearable for continuous, remote heart health monitoring with real-time alerts for both users and caregivers, emphasizing early detection and personal health management.

Choose Assert-IQ if…

Choose Assert-IQ if your healthcare system requires a long-term, highly reliable, and minimally invasive solution for continuous cardiac monitoring in patients with suspected heart rhythm disorders. This tool is ideal for comprehensive arrhythmia detection and management within a clinical setting, offering robust data for physician diagnosis and treatment planning over several years.

View Assert-IQ →

Choose Cardiomo if…

Choose Cardiomo if you need a flexible, patient-centric wearable solution for continuous remote heart health monitoring and early detection of cardiovascular events. This tool is best suited for individuals and caregivers who benefit from real-time alerts, mobile accessibility, and the convenience of a medical-grade patch for ongoing vital sign tracking in a home or outpatient setting.

View Cardiomo →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Assert-IQ Cardiomo
Pricing Enterprise Contact for pricing
Deployment Hybrid Cloud-based with wearable device and mobile app
FDA Status Cleared AI-estimated Unknown
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Assert-IQ is a minimally invasive insertable device, offering long-term, continuous monitoring without patient interaction after insertion, which enhances passive usability. Cardiomo is a wearable patch with a mobile app, requiring patient adherence for wearing and charging, but offering a user-friendly interface for real-time data and alerts. Both aim for ease of use in their respective contexts, making it a tie.

Clinical Value

Assert-IQ

Assert-IQ provides long-term continuous cardiac monitoring for up to 6 years and uses advanced AI algorithms to reduce false positives and improve accuracy in arrhythmia detection, which is crucial for clinical decision-making. Cardiomo offers continuous vital sign monitoring and AI-powered disease detection with real-time alerts, but its clinical validation and longevity are not as extensively detailed for long-term, physician-focused diagnostic use.

Pricing & Value

Tie

Both tools lack transparent public pricing, making a direct comparison of value difficult. Assert-IQ is an enterprise-focused solution requiring contact with Abbott Medical for institutional pricing. Cardiomo previously offered a consumer price with a monthly subscription, but current pricing is not publicly available.

Enterprise Readiness

Assert-IQ

Assert-IQ is designed for large health systems, hospitals, and cardiology clinics, offering secure cloud-based data, remote monitoring, proactive clinician alerts, and remote programmability, indicating strong enterprise readiness. While Cardiomo is HIPAA-compliant and offers cloud analytics, its primary focus appears to be a B2B and B2B2C model, and its enterprise-specific features and integrations are not as clearly defined as Assert-IQ's.

Innovation

Assert-IQ

Assert-IQ stands out with its combination of AI algorithms, the world's longest-lasting Bluetooth-enabled ICM (up to 6 years), and IQ Insights for comprehensive cardiovascular health trends. Cardiomo utilizes AI for disease detection and offers a medical-grade wearable patch with a long battery life, but Assert-IQ's integrated AI for false positive reduction and extended monitoring duration represent a more significant leap in the ICM space.

Support & Docs

Assert-IQ

Abbott Medical, as a large established company, provides comprehensive support and documentation for Assert-IQ, including clinician manuals, patient guides, remote programming guides, and dedicated technical support. Cardiomo's documentation and support details are less publicly available, though it does offer a mobile application for users and alerts for caregivers.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Assert-IQ Cardiomo
Name Assert-IQ Cardiomo
Company Abbott Medical Cardiomo, Inc.
Description The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. Cardiomo offers a medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers.
Mobile App None Android and iOS
Key Features Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion Medical-grade wearable patch, Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature), AI-powered disease detection (arrhythmias, cardiovascular events), Real-time alerts and notifications, Mobile application (Android and iOS), HIPAA-compliant cloud analytics, Fall detection, Long battery life (up to 7-10 days)

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Cardiomo.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Assert-IQ is designed to streamline data management and physician workflow with remote programming capabilities and real-time data transmission to a clinic's portal. Cardiomo, as a wearable device with a mobile app and cloud analytics, aims to keep clinicians informed with real-time data dashboards and alerts, though specific EHR integration depth is not detailed. Generally, EHR integration of patient-generated health data from wearables is evolving, with challenges in unstructured data and clinician overload.
Assert-IQ ICM has demonstrated high accuracy in detecting atrial fibrillation (AF), with a 99.4% episode-based sensitivity and 93.0% duration-based sensitivity compared to Holter monitoring, and its AI algorithms reduce false positives while maintaining high sensitivity. Cardiomo's proprietary AI algorithms are trained to detect arrhythmias and other cardiovascular diseases, analyzing biosensor data to spot abnormalities and provide real-time alerts.
Assert-IQ aims to simplify clinic workflows and reduce data burden through its advanced algorithms and remote programming, suggesting a focus on ease of use for clinicians. Cardiomo is described as a user-friendly and practical solution for monitoring heart health, implying a relatively low learning curve for both patients and clinicians.
Abbott Medical offers a SyncUP Remote Monitoring Support team for Assert-IQ to assist patients with app setup and ensure timely data transmission, and provides weekly compliance reports to streamline workflow. Cardiomo's platform provides instant notifications to patients, relatives, and care providers, and aims to reduce the distance between patient and practitioner, suggesting a supportive ecosystem.
Assert-IQ, as an insertable cardiac monitor with up to 6 years of continuous monitoring, is particularly suited for long-term, comprehensive arrhythmia detection and management, especially for patients with suspected heart rhythm disorders, cryptogenic stroke, or those undergoing ablation procedures. Cardiomo, a medical-grade wearable patch with continuous vital sign monitoring and real-time alerts, appears well-suited for remote heart health monitoring, early detection of cardiovascular diseases, and providing timely alerts to users and caregivers, potentially for a broader population at risk of CVDs.

Backers

Who funded each tool's parent company.

Cardiomo

AI Tool Finder
AI-powered search. Results may not be comprehensive.